Skip to main content
. 2014 Mar 14;10(6):1661–1668. doi: 10.4161/hv.28350

Table 1. Characteristics of studies describing plasma and memory B cell kinetics following immunization with glycoconjugate vaccines.

Study reference Age
(y)
Number of samples
per study time point*
Vaccine Carrier protein Number of priming doses
[time since last vaccination]
Study time points (days)
Plasma cells            
Kelly et al.7 13–15 3–34 MenCCV CRM197 1 [2–3 y] 0, 3, 4, 5, 6, 7, 8, 9, 10, 12, 28
Clutterbuck et al.6 28–44 6 PCV-7† CRM197 1 [1 y] 0, 6, 7, 15
Blanchard Rohner et al.5 1 5–26 MenCCV CRM197 3 [8 mo] 0, 2, 4, 6, 8, 9, 30
Kelly et al.8 0.17 33 MenCCV CRM197 - 4, 6, 8, 10, 12, 14, 16, 30
Kelly et al.8 0.33 29 MenCCV CRM197 2 [1 mo] 4, 6, 8, 10, 12, 14, 16
             
Memory B cells            
Kelly et al.7 13–15 3–40 MenCCV CRM197 1 [2–3 y] 0, 3, 4, 5, 6, 7, 28, 365
Clutterbuck et al.6 28–44 6 PCV-7† CRM197 1 [1 y] 0, 6, 7, 15, 28
Blanchard Rohner et al.5 1 4–28 MenCCV CRM197 3 [8 mo] 0, 2, 4, 6, 8, 9, 30
Kelly et al.8 0.17 31 MenCCV CRM197 - 4, 6, 8, 10, 12, 14, 16, 30
Kelly et al.8 0.33 17 MenCCV CRM197 2 [1 mo] 4, 6, 8, 12, 14, 16, 30
Perrett et al.9 7 52 MenCCV TT 3 [6 y] 0, 7, 28, 365
Perrett et al.9 8 25 MenCCV TT 2 [6 y] 0, 28, 365
Perrett et al.9 8.3 53 MenCCV TT 1 [6 y] 0, 7, 28, 365
Perrett et al.9 9.3 30 MenCCV TT 1 [6 y] 0, 28, 365
Perrett et al.9 10.3 27 MenCCV TT 1 [6 y] 0, 28, 365
Perrett et al.9 11.3 27 MenCCV TT 1 [6 y] 0, 28, 365
Perrett et al.9 12.1 29 MenCCV TT 1 [6 y] 0, 7, 28, 365
*

Number of samples between study time points may differ markedly and the range is given if known, otherwise the total number of samples is shown; †Values from serotype 4 were used to describe plasma and memory B cell kinetics; CRM197, cross-reactive material (non- toxic recombinant form of diphtheria toxin); MenCCV, meningococcal serogroup C conjugate vaccine; PCV-7, 7-valent pneumococcal conjugate vaccine; TT, tetanus toxoid.